Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03546322 · ClinicalTrials.gov registry record
Customized Registry Tool for Tracking Adherence to Clinical Guidelines for Head and Neck Cancers
A clinical trial, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 802
- Enrollment target
NCT03546322: Completed study, sponsored by University of California, San Francisco.
NCT03546322 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 802 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03546322 has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 802 participants
- Enrollment target
Study Summary
To implement and evaluate a health information technology platform designed to support the management of patients with head and neck cancer in an urban, publicly-funded outpatient setting. This is an observational study; researchers will not assign specific interventions to study participants.
Primary Outcome
Time from diagnosis to initiation of treatment
Interventions
- OTHER Registry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 802 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2022-03-30 |
What the finished NCT03546322 record still lists
NCT03546322 is an observational study that tracks outcomes without assigning an intervention. The registered 802 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Registry is the first listed.
NCT03546322 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03546322 about?
NCT03546322 is a clinical study titled "Customized Registry Tool for Tracking Adherence to Clinical Guidelines for Head and Neck Cancers". To implement and evaluate a health information technology platform designed to support the management of patients with head and neck cancer in an urban, publicly-funded outpatient setting. This is an observational study; researchers will not assign specific interventions to study participants.
What is the current status of trial NCT03546322?
This trial is currently completed. The enrollment target is 802 participants. The study started on 2018-06-01. Estimated completion is 2022-03-30.
What interventions are being tested in trial NCT03546322?
The interventions under investigation include: Registry (OTHER).
Who is sponsoring clinical trial NCT03546322?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03524430 · 801 participants · NA
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
- NCT04423211 · 804 participants · Phase 3
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- NCT06522022 · 804 participants · NA
PTSD Screening in Pregnant Black Women
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI